Compare NCSM & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NCSM | ENGN |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.6M | 117.2M |
| IPO Year | 2017 | 2023 |
| Metric | NCSM | ENGN |
|---|---|---|
| Price | $49.83 | $1.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $21.08 |
| AVG Volume (30 Days) | 5.3K | ★ 703.0K |
| Earning Date | 04-29-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 239.22 | 56.85 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $142,471,000.00 | N/A |
| Revenue This Year | $5.57 | N/A |
| Revenue Next Year | $4.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $34.06 | $1.40 |
| 52 Week High | $87.36 | $12.25 |
| Indicator | NCSM | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 55.55 | 47.73 |
| Support Level | $42.69 | $1.67 |
| Resistance Level | $51.69 | $1.84 |
| Average True Range (ATR) | 1.26 | 0.07 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 69.45 | 48.94 |
NCS Multistage Holdings Inc is a provider of engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completion, and field development strategies. The company provides its products and services to E&P companies for use in onshore and offshore wells, predominantly those drilled with horizontal laterals in unconventional and conventional oil and natural gas formations. It also provides tracer diagnostics services and sells products for well construction including casing buoyancy systems, liner hanger systems and toe initiation sleeves, along with certain complementary products from third parties. The company operates in the United States, Canada and other countries, with the majority of its revenue generated from Canada.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.